Commentary Open Access
Volume 3 | Issue 6 | DOI: https://doi.org/10.33696/immunology.3.122
Targeting Ovarian Cancer with IL-2 Cytokine/Antibody Complexes: A Summary and Recent Advances
Yilun Deng1, Ryan M Reyes2,3, Chenghao Zhang1,4, José Conejo-Garcia5, Tyler J. Curiel1,2,3,6,*
- 1Discipline of Pharmacology, School of Pharmacy, University of the Western Cape, Bellville 7535, South Africa
- 2Department of Chemistry, University of the Western Cape, Bellville 7535, South Africa
- 3South African Herbal Science and Medicine Institute, University of the Western Cape, Bellville 7535, South Africa
- 4Discipline of Pharmaceutics, School of Pharmacy, University of the Western Cape, Bellville 7535, South Africa
- 5South African Herbal Science and Medicine Institute, University of the Western Cape, Bellville 7535, South Africa
- 6Discipline of Pharmaceutics, School of Pharmacy, University of the Western Cape, Bellville 7535, South Africa
Corresponding Author
Tyler Curiel, curielt@uthscsa.edu
Received Date: August 12, 2021
Accepted Date: December 04, 2021
Deng Y, Reyes RM, Zhang C, Conejo-Garcia J, Curiel TJ. Targeting Ovarian Cancer with IL-2 Cytokine/Antibody Complexes: A Summary and Recent Advances. J Cell Immunol. 2021;3(6):387-396.
Copyright: © 2021 Deng Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Ovarian cancer, Immunotherapy, IL-2, Regulatory T cell, IL-2 receptor
Recommended Articles
Chimeric Antigen Receptor CAR NK Cells Emerging Immunotherapy for the Treatment of Cancer
Although NK cells are recognized as effector lymphocytes of the innate immune system, they also regulate the adaptive immune response by releasing inflammatory cytokines and developing immunological memory. Unlike other lymphocytes such as T or B cells, NK cells do not express rearrangeable, antigen-specific receptors.
Deubiquitinase as Potential Targets for Cancer Immunotherapy
During the last few decades, immunotherapy is considered to be an important approach to help our immune system to fight various kinds of diseases, such as tumor. Sometimes, it works very well for some types of cancers, for example: bladder cancer, colorectal cancer, breast cancer and lymphoma.
Role of the Gut Microbiome in the Modulation of Cancer Immunotherapy Response
The gut microbiome or gut flora is a vast community of microorganisms such as bacteria, viruses, protozoa, and fungi that inhabit the digestive tract of the human and other animals. In the human body, bacterial species colonize into the oral cavity, skin, vagina, and placenta, however, the largest population of microorganisms resides in the intestine. The majority of gut microbiota belong to the phyla Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria.
CTLA-4 and PD-L1 or PD-1 Pathways: Immune Checkpoint Inhibitors and Cancer Immunotherapy
The immune system developed certain checks and balance to control or inhibit the reactivity against normal cells of the body. Uncontrolled immune responses to the non-self entities such as bacteria, viruses, parasites, or mutated self-antigens can cause an inflammatory reaction and autoimmune diseases.
Cancer Nanomedicine: Strategies to Enhance Tumor Delivery and Immunotherapy
Cancer nanomedicine was originally developed for more efficient delivery of chemotherapeutic agents into tumor, and has been extensively employed as a therapeutic for cancer treatment owing to its unique features in drug delivery, diagnosis and imaging, as well as the therapeutic nature of some nanomaterials themselves.